25/01/2025
"Once-weekly Insulin Icodec: A Game-Changer in Diabetes Management"
Insulin Icodec is a once-weekly basal insulin injection made by Novo Nordisk that is expected to be approved by DCGA of India for import and sale in India. It is used for the treatment of type 2 and type 1 diabetes as an alternative to daily Insulin Glargine & Insulin Degludec injections.
Key Features of Insulin Icodec:
• Effectiveness: The ONWARDS clinical trials have shown that Insulin Icodec has the same efficacy in lowering HbA1c levels as compared with daily Insulin Glargine and Insulin Degludec.
• Safety Profile: The risk of hypoglycemia is the same as Insulin Glargine and Degludec
• Glucose Regulation: Maintains stable blood sugar levels throughout the week.
• Not yet approved by US-FDA
• Already been Approved in Canada, EU, Australia, Japan and Switzerland for the treatment of both Type 1 and Type 2 diabetes. In China, for the treatment of type 2 diabetes.
Insulin Icodec could transform diabetes treatment by reducing injection frequency, improving adherence, and simplifying care. This innovation is particularly beneficial for individuals with busy lifestyles or difficulties managing daily regimens. Consult with Dr Om Prakash, MBBS, MD Internal Medicine, the Best Consultant Physician in Noida specialising in the treatment of both type 1 and type 2 diabetes and its complications.
, , , , , , ,